GnRH agonists as contraceptive agents: Predicted significantly reduced risk of breast cancer
- 30 September 1991
- journal article
- review article
- Published by Elsevier in Contraception
- Vol. 44 (3) , 289-310
- https://doi.org/10.1016/0010-7824(91)90019-c
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Age-related factors in cancers of the breast, ovary, and endometriumJournal of Chronic Diseases, 1987
- Ovulation inhibition with nafarelin acetate nasal administration for six monthsContraception, 1985
- Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding *Fertility and Sterility, 1985
- CONTRACEPTION WITH AN LHRH AGONIST: EFFECT ON GONADOTROPHIN AND STEROID SECRETION PATTERNSClinical Endocrinology, 1984
- Peptide Contraception in WomenUpsala Journal of Medical Sciences, 1984
- SUSTAINED GONADAL SUPPRESSION IN FERTILE WOMEN WITH THE LHRH AGONIST BUSERELINClinical Endocrinology, 1983
- Luteal Phase Defects Induced by an Agonist of Luteinizing Hormone-Releasing Factor: A Model for Fertility ControlScience, 1982
- Failure to Interrupt Established Pregnancy in Humans by d-Tryptophan-6-Luteinizing Hormone-Releasing HormoneFertility and Sterility, 1981
- Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?Contraception, 1981
- Induction of Luteolysis in the Human with a Long-Acting Analog of Luteinizing Hormone-Releasing FactorScience, 1979